Home ETF List About

ETF Holdings Breakdown of CRNX

Stock NameCrinetics Pharmaceuticals Inc
TickerCRNX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS22663K1079
LEI549300Q1CNFXK5P31D28

CRNX institutional holdings

The following institutional investment holdings of CRNX have been identified

Date ETF ISIN/Name Num Shares Book value
2025-10-17 IE00B3VWM098 (iShares VII PLC - iShares MSCI USA Small Cap ESG Enhanced ETF USD Acc) 71,609USD 2,976,786
2025-10-17 IE00BYXG2H39 (iShares Nasdaq US Biotechnology UCITS ETF USD (Acc)) 59,933USD 2,491,415
2025-10-17 IE00BDZVHG35 (iShares Nasdaq US Biotechnology UCITS ETF USD (Dist)) 59,933USD 2,491,415
2025-10-17 IE00BF4RFH31 (iShares MSCI World Small Cap UCITS ETF USD (Acc)) 57,840USD 2,404,409
2025-10-17 IE000T9EOCL3 (iShares MSCI World Small Cap ESG Enhanced UCITS ETF USD (Acc)) 5,579USD 231,919
Total =254,894 USD 10,595,944
Book value of shares is calculated on the adjusted close price of each day (row).

News associated with CRNX

Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives $68.86 Consensus Price Target from Brokerages
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been given a consensus rating of “Moderate Buy” by the nine research firms that are covering the stock, Marketbeat.com reports. Two research analysts have rated the stock with a hold recommendation and seven have issued a buy recommendation on the company. The average twelve-month price objective […] - 2025-08-19 02:16:54
Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Cut to $86.00 by Analysts at JMP Securities
Crinetics Pharmaceuticals (NASDAQ:CRNX – Free Report) had its target price reduced by JMP Securities from $90.00 to $86.00 in a report published on Monday,Benzinga reports. JMP Securities currently has a market outperform rating on the stock. Several other research firms have also recently weighed in on CRNX. HC Wainwright reaffirmed a “buy” rating and set […] - 2025-08-12 04:47:05
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Sold by Victory Capital Management Inc.
Victory Capital Management Inc. lowered its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 10.7% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 251,331 shares of the company’s stock after selling 30,120 shares during the quarter. Victory Capital Management Inc.’s holdings in […] - 2025-07-25 06:06:53
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Recommendation of “Moderate Buy” from Brokerages
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has been given an average recommendation of “Moderate Buy” by the ten brokerages that are currently covering the firm, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. The average 12-month target price […] - 2025-07-22 07:55:07
New York State Common Retirement Fund Sells 17,508 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
New York State Common Retirement Fund lessened its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 11.3% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 137,918 shares of the company’s stock after selling 17,508 shares during the quarter. New York State Common […] - 2025-07-22 07:13:05
Teacher Retirement System of Texas Decreases Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Teacher Retirement System of Texas decreased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 6.5% in the 1st quarter, Holdings Channel reports. The fund owned 22,442 shares of the company’s stock after selling 1,561 shares during the quarter. Teacher Retirement System of Texas’ holdings in Crinetics Pharmaceuticals were worth $753,000 […] - 2025-07-15 04:24:35
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Consensus Rating of “Moderate Buy” from Brokerages
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat.com reports. One analyst has rated the stock with a hold rating and nine have given a buy rating to the company. The average 1 year […] - 2025-07-02 04:30:55
Insider Selling: Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Insider Sells $3,141,877.09 in Stock
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) insider Stephen F. Betz sold 97,483 shares of the stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $32.23, for a total transaction of $3,141,877.09. Following the transaction, the insider now owns 99,713 shares of the company’s stock, valued […] - 2025-06-19 05:10:52
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Acquired by Mackenzie Financial Corp
Mackenzie Financial Corp grew its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 8.8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,422 shares of the company’s stock after purchasing an additional 440 shares during the period. Mackenzie Financial Corp’s holdings […] - 2025-06-05 06:18:55
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Receives Average Rating of “Moderate Buy” from Brokerages
Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) have received an average rating of “Moderate Buy” from the eleven ratings firms that are presently covering the stock, MarketBeat reports. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the company. The average 1 […] - 2025-06-02 02:10:52
State of Wyoming Makes New Investment in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
State of Wyoming purchased a new stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 985 shares of the company’s stock, valued at approximately $50,000. Several other large investors […] - 2025-05-30 05:06:48
Bank of America Corp DE Cuts Stock Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Bank of America Corp DE decreased its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 15.4% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 235,281 shares of the company’s stock after selling 42,792 shares during the period. Bank of America Corp DE’s holdings in Crinetics Pharmaceuticals were worth $12,030,000 […] - 2025-05-23 06:26:56
BNP Paribas Financial Markets Sells 5,683 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
BNP Paribas Financial Markets decreased its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 27.1% in the fourth quarter, Holdings Channel.com reports. The fund owned 15,259 shares of the company’s stock after selling 5,683 shares during the period. BNP Paribas Financial Markets’ holdings in Crinetics Pharmaceuticals were worth $780,000 at the […] - 2025-05-23 04:58:51
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. Purchases 6,719 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 53,163 shares of the company’s stock after acquiring an additional 6,719 shares during […] - 2025-05-21 05:40:53
Ameriprise Financial Inc. Has $18.16 Million Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Ameriprise Financial Inc. lifted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 110.8% during the fourth quarter, Holdings Channel reports. The fund owned 355,174 shares of the company’s stock after buying an additional 186,681 shares during the quarter. Ameriprise Financial Inc.’s holdings in Crinetics Pharmaceuticals were worth $18,159,000 as of […] - 2025-05-16 05:03:19
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Recommendation of “Moderate Buy” by Analysts
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Get Free Report) has earned an average recommendation of “Moderate Buy” from the thirteen brokerages that are presently covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and twelve have assigned a buy recommendation to the company. The average 1 year target […] - 2025-05-08 02:22:53
Envestnet Asset Management Inc. Buys 8,751 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Envestnet Asset Management Inc. boosted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 16.1% during the 4th quarter, HoldingsChannel reports. The fund owned 63,077 shares of the company’s stock after buying an additional 8,751 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Crinetics Pharmaceuticals were worth $3,225,000 as […] - 2025-04-25 04:24:46
Legal & General Group Plc Buys 12,538 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Legal & General Group Plc lifted its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 16.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 88,939 shares of the company’s stock after acquiring an additional 12,538 shares during the quarter. Legal & General Group Plc’s holdings in Crinetics Pharmaceuticals were worth $4,547,000 as […] - 2025-04-22 04:47:14
Crinetics Pharmaceuticals (NASDAQ:CRNX) Shares Unloaded Rep. Josh Gottheimer
Representative Josh Gottheimer (D-New Jersey) recently sold shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX). In a filing disclosed on April 10th, the Representative disclosed that they had sold between $1,001 and $15,000 in Crinetics Pharmaceuticals stock on March 19th. The trade occurred in the Representative’s “MORGAN STANLEY – SELECT UMA ACCOUNT # 1” account. Representative Josh […] - 2025-04-14 03:02:59
Corebridge Financial Inc. Buys 1,992 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Corebridge Financial Inc. boosted its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 4.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 43,599 shares of the company’s stock after buying an additional 1,992 shares during the period. Corebridge Financial Inc.’s holdings […] - 2025-04-02 06:46:52
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Shares Bought by Vanguard Group Inc.
Vanguard Group Inc. grew its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 44.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,089,391 shares of the company’s stock after acquiring an additional 2,801,736 shares during the quarter. Vanguard Group […] - 2025-04-02 05:24:53
16,000 Shares in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Purchased by KLP Kapitalforvaltning AS
KLP Kapitalforvaltning AS bought a new position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 16,000 shares of the company’s stock, valued at approximately $818,000. A number of other hedge funds have also added to […] - 2025-04-01 05:14:54
Crinetics Pharmaceuticals (NASDAQ:CRNX) Coverage Initiated at Stifel Nicolaus
Analysts at Stifel Nicolaus began coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) in a report released on Tuesday, MarketBeat Ratings reports. The firm set a “buy” rating and a $60.00 price target on the stock. Stifel Nicolaus’ price target would suggest a potential upside of 73.86% from the stock’s previous close. […] - 2025-03-27 04:00:59
Arizona State Retirement System Grows Holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Arizona State Retirement System boosted its holdings in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 21.6% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 23,469 shares of the company’s stock after purchasing an additional 4,168 shares during the […] - 2025-03-14 06:10:48
Assetmark Inc. Purchases 1,014 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Assetmark Inc. raised its position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 5.9% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 18,161 shares of the company’s stock after acquiring an additional 1,014 shares during the quarter. Assetmark Inc.’s holdings in Crinetics Pharmaceuticals […] - 2025-03-12 06:11:03
Keybank National Association OH Has $478,000 Position in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Keybank National Association OH boosted its stake in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.4% in the 4th quarter, HoldingsChannel.com reports. The fund owned 9,352 shares of the company’s stock after purchasing an additional 1,176 shares during the quarter. Keybank National Association OH’s holdings in Crinetics Pharmaceuticals were worth $478,000 at […] - 2025-03-10 05:54:54
Handelsbanken Fonder AB Buys 2,800 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
Handelsbanken Fonder AB raised its stake in Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 14.7% during the fourth quarter, Holdings Channel.com reports. The institutional investor owned 21,800 shares of the company’s stock after purchasing an additional 2,800 shares during the quarter. Handelsbanken Fonder AB’s holdings in Crinetics Pharmaceuticals were worth $1,115,000 at the end […] - 2025-02-28 07:25:04
New York State Common Retirement Fund Purchases 7,735 Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX)
New York State Common Retirement Fund lifted its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 5.2% during the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 155,426 shares of the company’s stock after purchasing an additional 7,735 shares during the quarter. New York State Common Retirement Fund’s holdings in Crinetics […] - 2025-02-27 06:51:01
TD Cowen Begins Coverage on Crinetics Pharmaceuticals (NASDAQ:CRNX)
Analysts at TD Cowen started coverage on shares of Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) in a research note issued on Tuesday, MarketBeat.com reports. The firm set a “buy” rating on the stock. CRNX has been the subject of a number of other reports. Wolfe Research started coverage on shares of Crinetics Pharmaceuticals in […] - 2025-02-13 08:26:44

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.